Driven by advancements in genomic profiling, omics, and AI technologies, the biomarkers and diagnostics field continues to surge, with Roche and AstraZeneca’s world-first digital pathology CDx approval in April taking the number of approved CDx tests to a record high of 188.

We are now witnessing a need for new, stronger co-development partnerships to validate novel biomarkers, navigate global in vitro diagnostic regulation, and harmonize commercialization; which will in turn accelerate adoption of these drug-diagnostics across diverse therapeutic areas and markets.

Returning for its 15th anniversary this September, the World Clinical Biomarkers & Companion Diagnostics Summit will unite 600+ industry leaders across biopharma, CDx developers, testing labs, regulators, and payers to advance clinical biomarker strategies and accelerate drug-diagnostics to market for improved patient diagnosis, stratification, and monitoring.

See the event details here.